Status:
TERMINATED
Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Pain
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Giving medications in different ways may change their effectiveness in controlling pain. It is not yet known whether intrathecal therapy is more effective than standard therapy in controlli...
Detailed Description
OBJECTIVES: Primary * To compare the effectiveness of pain control comprising intrathecal opioid delivery versus the standard analgesia-delivery method in patients with locally advanced, unresectabl...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Inclusion criteria:
- Histologically confirmed adenocarcinoma of the pancreas
- Mixed adenocarcinoma tumors allowed provided the predominant invasive component of the tumor is adenocarcinoma
- Locally advanced, unresectable, or metastatic disease
- Patients must be within two months of diagnosis or have started chemotherapy within 60 days of study
- Average pain score ≥ 4/10 over a 7-day period on a verbal numerical rating scale
- Exclusion criteria:
- Known brain metastases
- Tumor with clinically significant obstruction of the spinal canal
- PATIENT CHARACTERISTICS:
- Inclusion criteria:
- Karnofsky performance status 60-100%
- ANC ≥ 1,500 cells/mm³
- Hematocrit ≥ 28%
- WBC ≥ 3,500 cells/mm³
- Platelets ≥ 90,000/mm³
- Serum creatinine ≤ 2.0 mg/dL
- Bilirubin ≤ 2.5 mg/dL
- AST/ALT ≤ 5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 5 times ULN
- INR ≤ 1.5
- Not pregnant or nursing
- Negative pregnancy test
- Mini-mental status exam score ≥ 22
- Exclusion criteria:
- Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy, including any of the following:
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
- Active peptic ulcer disease
- Active infections
- Insensitive to opioid medication for cancer pain
- Insufficient tissue or decubitus ulcer near device implantation site
- Current history of substance abuse
- PRIOR CONCURRENT THERAPY:
- Minor procedures (i.e., dental work or skin biopsy), tumor biopsies, and biliary stent placement are allowed
- No prior surgical procedures affecting absorption
- Prior or other concurrent pain medications are allowed
- Concurrent chemotherapy or radiotherapy allowed at the discretion of the treating physician
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00660348
Start Date
March 1 2008
End Date
March 1 2011
Last Update
October 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410